JA
REGN icon

JOYN Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

JOYN Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-234
Closed -$87K – 1096
2018
Q4 		$87K Buy
234
+21
+10% +$7.69K 0.02% 219
2018
Q3 		$86K Buy
213
+2
+0.9% +$761 0.02% 254
2018
Q2 		$73K Buy
211
+199
+1,658% +$62.2K 0.02% 302
2018
Q1 		$4K Buy
+12
New +$4.17K ﹤0.01% 919

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JOYN Advisors's REGN Position: Q1 2019 in Review

JOYN Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2019, closing a stake of 234 shares — an estimated $87K sold.

JOYN Advisors first reported a position in REGN in Q1 2018 and held it in 4 quarters. The position peaked at $87K in Q4 2018. 718 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

  • JOYN Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • JOYN Advisors sold 234 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $87K.
  • JOYN Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 4 quarters.
  • JOYN Advisors's Regeneron Pharmaceuticals position peaked at $87K in Q4 2018.
  • 718 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on JOYN Advisors's 13F filing for Q1 2019, filed 9 May 2019.